|Bid||0.00 x 0|
|Ask||2,309.30 x 0|
|Day's Range||2,272.50 - 2,309.00|
|52 Week Range||1,642.00 - 2,369.80|
|PE Ratio (TTM)||32.47|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2,470.00|
The U.S. Senate on Monday confirmed lawyer Andrei Iancu as the next head of the U.S. Patent and Trademark Office, clearing the way for him to lead an agency tasked with deciding who owns the rights to inventions in areas like software, pharmaceuticals, and medical devices. The Senate voted 94-0 to confirm Iancu, 49, who was nominated by President Donald Trump in August. Silicon Valley firms like Alphabet Inc and Facebook Inc have urged the agency to review applications more carefully, saying in the past it granted too many dubious patents that lead to nuisance lawsuits.
India has granted Pfizer Inc a patent for its powerful pneumonia vaccine Prevenar 13, in a blow to some health groups that said this would put the treatment out of reach of thousands in poorer nations. The decision by India's patent office bars other companies from making cheaper copies of the vaccine and allows Pfizer to exclusively sell it in India until 2026.